Focus

Shionogi

LATEST

Asia & Pacific
Asia & Pacific

Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint

Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint
|
Companies
Companies

Japan’s Shionogi Says COVID-19 Pill Shows Rapid Clearance of Virus

Japan’s Shionogi Says COVID-19 Pill Shows Rapid Clearance of Virus
|
Markets
Markets

Japan-Based Shionogi’s COVID-19 Drug Associated With Birth Defects: Bloomberg

Japan-Based Shionogi’s COVID-19 Drug Associated With Birth Defects: Bloomberg
|
Asia & Pacific
Asia & Pacific

Japan’s Shionogi Seeks Approval for COVID-19 Pill

Japan’s Shionogi Seeks Approval for COVID-19 Pill
|
Companies
Companies

Japan’s Shionogi Starts Phase III Clinical Trial in Vietnam for COVID-19 Vaccine

Japan’s Shionogi Starts Phase III Clinical Trial in Vietnam for COVID-19 Vaccine
|
Asia & Pacific
Asia & Pacific

Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint

Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint
|
Companies
Companies

Japan’s Shionogi Says COVID-19 Pill Shows Rapid Clearance of Virus

Japan’s Shionogi Says COVID-19 Pill Shows Rapid Clearance of Virus
|
Markets
Markets

Japan-Based Shionogi’s COVID-19 Drug Associated With Birth Defects: Bloomberg

Japan-Based Shionogi’s COVID-19 Drug Associated With Birth Defects: Bloomberg
|
Asia & Pacific
Asia & Pacific

Japan’s Shionogi Seeks Approval for COVID-19 Pill

Japan’s Shionogi Seeks Approval for COVID-19 Pill
|
Companies
Companies

Japan’s Shionogi Starts Phase III Clinical Trial in Vietnam for COVID-19 Vaccine

Japan’s Shionogi Starts Phase III Clinical Trial in Vietnam for COVID-19 Vaccine
|